A Stanford research team investigating a new immunotherapy approach, which consists of injecting tiny amounts of two immuno-stimulating molecules directly into the cancers themselves, announced good news. The first of the two injections contained a CpG oligonucleotide a short stretch of DNA that promotes the expression of OX40, a protein that resides on the surface of the immune system’s T cells. The second injection comprised an antibody that binds to OX40 and directs the T cells to eliminate cancer cells.
The treatment seems to have worked well in mice with lymphoma, breast, colon . . .